1 / 23

Polymerisation Chemistry

Polymerisation Chemistry. P4 – Case Studies. Hyperbranched PMMA (HB-PMMA) Hyperbranched aliphatic polyurethanes (HB-PU) Highly syndiotactic PMMA and block copolymers at r.t. (S-PMMA) Novel polymer beads for solid-phase organic synthesis. HB-Polymers. Tunable viscosity

deacon
Download Presentation

Polymerisation Chemistry

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Polymerisation Chemistry

  2. P4 – Case Studies • Hyperbranched PMMA (HB-PMMA) • Hyperbranched aliphatic polyurethanes (HB-PU) • Highly syndiotactic PMMA and block copolymers at r.t. (S-PMMA) • Novel polymer beads for solid-phase organic synthesis

  3. HB-Polymers • Tunable viscosity • Modifiable solubilitycharacteristics • End-group dominatedproperties • One-pot synthesis • Reduced crystallinity • Increased blendcompatibility

  4. HB-PMMA • Solution polymerisation of MMA as batch model reaction • AIBN/xylenes; 20% MMA; time vs conversion; validation data • Solution polymerisation of HB-PMMA as batch model reaction • Independently reproduced • Scale-up of branching agent

  5. HB-PU • Small scale synthesis of HB-PU • Effect of reaction parameters investigated • Time, temperature, addition sequence, catalyst, solvent • Small scale synthesis of linear PU model polymer

  6. S-PMMA • Improved catalyst available • Better reaction control, higher syndiotacticity

  7. Polymer Beads • Successful catalyst optimisation (small scale) • Homogeneous crosslinking possible

  8. Immediate Targets I • PMMA scale-up reactor runs • Model validation Feedback loop established • Small scale HB-PMMA model reaction • HB-PMMA scale-up reactor runs • Implementation of new model

  9. Immediate Targets II • Complete kinetic data set for HB-PU • Small scale solution polymerisation • Conv., DoB, MW, MWD • Identify suitable matrix for MALDI-tof • Model implementation/validation

  10. Funding Opportunities • EPSRC • High-added value polymers (electronics, biomedical, pharmaceutical (enabling)) • MMI • LINK programme suggested • Huntsman • HB-PU – Synthesis and scale-up technology • Sign of interest

  11. Funding Opportunities • Avecia • CombiChem Supports – Synthesis and scale-up technology – immediate market potential • Initial discussion meeting 21.03.02 • BP/DTI • Photovoltaics/Molecular electronics contribution – IC Chem/ IC Physics initiative • Discussions needed • Basic Technology Initiative 2nd call • Do programme objectives match P4 philosophy?

  12. EPSRC Department of Trade & Industry Manufacturing Molecules Initiative “The overall objective is to help the UK to become the world’s leading manufacturing base of the next generation of complex, high value chemicals”

  13. 4 key aims • Reducing time taken to develop and make complex molecules (using both chemical & biological processes) • Improving competitiveness by using innovative processes & technologies • Raising skills, particularly in SMEs, to rapidly adopt new processes & technologies • Increasing awareness of new technologies and emerging best practice through networking • Reducing time taken to develop and make complex molecules (using both chemical & biological processes) • Improving competitiveness by using innovative processes & technologies • Raising skills, particularly in SMEs, to rapidly adopt new processes & technologies • Increasing awareness of new technologies and emerging best practice through networking

  14. Target Molecules • Pharmaceuticals including DNA active ingredients and those derived from human genome work • Intermediates for pharmaceuticals • Additives and dyestuffs • Chemicals for electronics, battery systems, memory, display and optical technologies • Agrochemicals • High performance materials for healthcare, packaging, housing, clothing, transport, etc. • Pharmaceuticals including DNA active ingredients and those derived from human genome work • Intermediates for pharmaceuticals • Additives and dyestuffs • Chemicals for electronics, battery systems, memory, display and optical technologies • Agrochemicals • High performance materials for healthcare, packaging, housing, clothing, transport, etc.

  15. Technical Priorities • New chiral formation or separation technologies • New catalysis technologies • Novel chemical synthesis • Innovative separation & reactor technologies • New media, such as supercritical and ionic fluids • New chiral formation or separation technologies • New catalysis technologies • Novel chemical synthesis • Innovative separation & reactor technologies • New media, such as supercritical and ionic fluids

  16. Technical Priorities • Enhanced fields such as photo, sonic, & microwave • Biological processing • Innovative process design • Characterisation of reactions • Novel pilot plant • On-line analysis & control • Enhanced fields such as photo, sonic, & microwave • Biological processing • Innovative process design • Characterisation of reactions • Novel pilot plant • On-line analysis & control

  17. Collaborative, pre-competitive research Collaborative, pre-competitive research What can we support? Scoping desk based research / survey /study < 4 months < £50k Pilot lab based research < 6 months < £100k Demo plant based proof of performance < 12 months < £100k

  18. Criteria for support of : • Min. One industrial and One research base partner • Pre-competitive research (not near to market) • Additionality (would not otherwise take place) • Exploitation (clearly identified route) • Overall limit 50% public funding (SMEs up to 60%)

  19. : CombiChem Supports • Min. One industrial and One research base partner • GSK, Pfizer, AstraZeneca • Pre-competitive research • Support performance and versatility, SPR tuned via synthesis • Additionality • Convincing • Exploitation • Clear • Overall limit 50% • Should be possible

  20. : Conducting Polymers • Min. One industrial and One research base partner • Merck, Avecia, SME?, IC Physics • Pre-competitive research • Scale-up, SPRs, composition • Additionality • Convincing • Exploitation • Needs to be worked out • Overall limit 50% • Needs to be negotiated

  21. Assessment Criteria : • Fit to aims and technical priorities (impact) • Quality of Science, Engineering & Technology (excellence) • Collaboration (mix of partners & disciplines) • Management (project plan & milestones) • Exploitation (route to market & plan)

  22. Approved projects • BRITEST Technology Transfer project • Chemicals Behaving Badly project • Chiral Separations Pilot study • Hyperbranched Polymers Pilot study

  23. Contact Point Richard Bahu MMI Programme Coordinator The Oxis Partnership April Croft Faringdon Road Shippon, Abingdon Oxfordshire OX13 6LN Tel/Fax: 01235 536766 E-mail: richardbahu@compuserve.com

More Related